Tuis300601 • SHE
add
Shenzhen Kangtai Biological Prods Co Ltd
Vorige sluiting
¥13,54
Dagwisseling
¥13,54 - ¥13,76
Jaarwisseling
¥12,93 - ¥23,45
Markkapitalisasie
15,20 mjd CNY
Gemiddelde volume
13,43 m
P/V-verhouding
100,69
Dividend-opbrengs
-
Primêre beurs
SHE
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (CNY) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 645,20 m | 42,85% |
Bedryfskoste | 424,14 m | 38,76% |
Netto inkomste | 22,43 m | -58,51% |
Netto winsgrens | 3,48 | -70,93% |
Wins per aandeel | — | — |
EBITDA | 127,47 m | 2,48% |
Effektiewe belastingkoers | 17,00% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (CNY) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 219,94 m | -77,94% |
Totale bates | 14,25 mjd | -5,10% |
Totale aanspreeklikheid | 4,57 mjd | -15,33% |
Totale ekwiteit | 9,68 mjd | — |
Uitstaande aandele | 1,12 mjd | — |
Prys om te bespreek | 1,56 | — |
Opbrengs op bates | 0,86% | — |
Opbrengs op kapitaal | 1,07% | — |
Kontantvloei
Netto kontantverandering
| (CNY) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 22,43 m | -58,51% |
Kontant van bedrywe | -46,30 m | 39,22% |
Kontant van beleggings | -65,23 m | 82,73% |
Kontant van finansiering | -98,94 m | -180,59% |
Netto kontantverandering | -210,53 m | 36,40% |
Beskikbare kontantvloei | -2,72 mjd | -245,41% |
Meer oor
Shenzhen Kangtai Biological Products, also known as BioKangtai, is a Chinese biopharmaceutical company that develops, manufactures and markets vaccines and other vaccine products.
Kangtai develops the Minhai COVID-19 vaccine and has the exclusive right to manufacture the Oxford–AstraZeneca COVID-19 vaccine in mainland China. Wikipedia
Gestig
08 Sep. 1992
Webwerf
Werknemers
1 913
